Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Gains from Investment Securities: 2020-2024

Historic Gains from Investment Securities for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to $3.7 million.

  • Xeris Biopharma Holdings' Gains from Investment Securities rose 475.90% to $478,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year decrease of 58.05%. This contributed to the annual value of $3.7 million for FY2024, which is 81.37% down from last year.
  • As of FY2024, Xeris Biopharma Holdings' Gains from Investment Securities stood at $3.7 million, which was down 81.37% from $20.0 million recorded in FY2023.
  • Over the past 5 years, Xeris Biopharma Holdings' Gains from Investment Securities peaked at $20.0 million during FY2023, and registered a low of $63,000 during FY2020.
  • Moreover, its 3-year median value for Gains from Investment Securities was $3.7 million (2024), whereas its average is $8.1 million.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Gains from Investment Securities surged by 4,182.69% in 2023 and then crashed by 81.37% in 2024.
  • Xeris Biopharma Holdings' Gains from Investment Securities (Yearly) stood at $63,000 in 2020, then skyrocketed by 747.62% to $534,000 in 2021, then fell by 12.36% to $468,000 in 2022, then surged by 4,182.69% to $20.0 million in 2023, then tumbled by 81.37% to $3.7 million in 2024.